B Dean

Summary

Affiliation: Mental Health Research Institute
Country: Australia

Publications

  1. ncbi Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use
    B Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Locked Bag 11, Parkville, Victoria 3052, Australia
    Neuroscience 103:9-15. 2001
  2. ncbi A predicted cortical serotonergic/cholinergic/GABAergic interface as a site of pathology in schizophrenia
    B Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Australia
    Clin Exp Pharmacol Physiol 28:74-8. 2001
  3. ncbi Studies on serotonergic markers in the human hippocampus: changes in subjects with bipolar disorder
    Brian Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    J Affect Disord 75:65-9. 2003
  4. ncbi Studies on dopaminergic and GABAergic markers in striatum reveals a decrease in the dopamine transporter in schizophrenia
    B Dean
    The Rebecca Cooper Research Laboratories, The Division of Molecular Schizophrenia, The Mental Health Research Institute, Victoria, 3052, Parkville, Australia
    Schizophr Res 52:107-14. 2001
  5. ncbi A change in the density of [(3)H]flumazenil, but not [(3)H]muscimol binding, in Brodmann's Area 9 from subjects with bipolar disorder
    B Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, The University of Melbourne, Parkville, Victoria, Australia
    J Affect Disord 66:147-58. 2001
  6. ncbi Extended treatment with typical and atypical antipsychotic drugs differential effects on the densities of dopamine D2-like and GABAA receptors in rat striatum
    B Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute, Parkville, Victoria, Australia
    Life Sci 69:1257-68. 2001
  7. ncbi Signal transmission, rather than reception, is the underlying neurochemical abnormality in schizophrenia
    B Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Australia
    Aust N Z J Psychiatry 34:560-9. 2000
  8. ncbi Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia
    E Scarr
    Centre for Neuroscience, The University of Melbourne, Parkville, Vic, Australia
    Mol Psychiatry 14:1017-23. 2009
  9. ncbi No change in the density of the serotonin1A receptor, the serotonin4 receptor or the serotonin transporter in the dorsolateral prefrontal cortex from subjects with schizophrenia
    B Dean
    The Division of Molecular Schizophrenia, The Mental Health Research Institute, Parkville, Victoria, Australia
    Neurochem Int 34:109-15. 1999
  10. ncbi A proposed pathological model in the hippocampus of subjects with schizophrenia
    E Scarr
    Rebecca L Cooper Research Laboratories, Division of Molecular Schizophrenia, The Mental Health Research Institute of Victoria, Parkville, Australia
    Clin Exp Pharmacol Physiol 28:70-3. 2001

Collaborators

Detail Information

Publications72

  1. ncbi Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use
    B Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Locked Bag 11, Parkville, Victoria 3052, Australia
    Neuroscience 103:9-15. 2001
    ..By contrast, changes in the density of cannabinoid-1 receptors may occur in the caudate-putamen in response to cannabis ingestion...
  2. ncbi A predicted cortical serotonergic/cholinergic/GABAergic interface as a site of pathology in schizophrenia
    B Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Australia
    Clin Exp Pharmacol Physiol 28:74-8. 2001
    ..4. From combining these data, a theoretical site is proposed that, if proven to exist in human cortex, is likely to be central to the pathology of that illness...
  3. ncbi Studies on serotonergic markers in the human hippocampus: changes in subjects with bipolar disorder
    Brian Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    J Affect Disord 75:65-9. 2003
    ..Various studies suggest the hippocampus and serotonergic systems are important in the pathology of bipolar disorder (BD). We therefore measured hippocampal serotonergic markers in post-mortem tissue from BD and control subjects...
  4. ncbi Studies on dopaminergic and GABAergic markers in striatum reveals a decrease in the dopamine transporter in schizophrenia
    B Dean
    The Rebecca Cooper Research Laboratories, The Division of Molecular Schizophrenia, The Mental Health Research Institute, Victoria, 3052, Parkville, Australia
    Schizophr Res 52:107-14. 2001
    ....
  5. ncbi A change in the density of [(3)H]flumazenil, but not [(3)H]muscimol binding, in Brodmann's Area 9 from subjects with bipolar disorder
    B Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, The University of Melbourne, Parkville, Victoria, Australia
    J Affect Disord 66:147-58. 2001
    ..This study examines the hypothesis that there are changes in cortical serotonergic, GABAergic and glutamatergic systems in bipolar disorder and schizophrenia...
  6. ncbi Extended treatment with typical and atypical antipsychotic drugs differential effects on the densities of dopamine D2-like and GABAA receptors in rat striatum
    B Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute, Parkville, Victoria, Australia
    Life Sci 69:1257-68. 2001
    ..The extent to which such changes are involved in the therapeutic effects of drugs such as olanzapine and clozapine remains to be determined...
  7. ncbi Signal transmission, rather than reception, is the underlying neurochemical abnormality in schizophrenia
    B Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Australia
    Aust N Z J Psychiatry 34:560-9. 2000
    ..This review aims to summarise the outcome of studies on changes in the molecular architecture of the brain of subjects with schizophrenia and formulate a hypothesis on mechanisms involved in the pathology of the illness...
  8. ncbi Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia
    E Scarr
    Centre for Neuroscience, The University of Melbourne, Parkville, Vic, Australia
    Mol Psychiatry 14:1017-23. 2009
    ....
  9. ncbi No change in the density of the serotonin1A receptor, the serotonin4 receptor or the serotonin transporter in the dorsolateral prefrontal cortex from subjects with schizophrenia
    B Dean
    The Division of Molecular Schizophrenia, The Mental Health Research Institute, Parkville, Victoria, Australia
    Neurochem Int 34:109-15. 1999
    ..These data suggest that not all serotonergic markers are altered in the dorsolateral prefrontal cortex from schizophrenic subjects...
  10. ncbi A proposed pathological model in the hippocampus of subjects with schizophrenia
    E Scarr
    Rebecca L Cooper Research Laboratories, Division of Molecular Schizophrenia, The Mental Health Research Institute of Victoria, Parkville, Australia
    Clin Exp Pharmacol Physiol 28:70-3. 2001
    ..The model we propose allows us to construct further studies that will test the consequences of such a hyperserotonergic state in the hippocampal formation. This model has the potential to open new avenues in schizophrenia research...
  11. ncbi Clozapine and olanzapine treatment decreases rat cortical and limbic GABA(A) receptors
    D Farnbach-Pralong
    The Rebecca L Cooper Research Laboratories, The Molecular Schizophrenia Division, The Mental Health Research Institute, Parkville, Victoria, Australia
    Eur J Pharmacol 349:R7-8. 1998
    ..1 and 1 mg kg(-1) day(-1)) markedly decreased the density of GABA(A) receptors in these two brain regions. These data suggest that modulation of GABAergic transmission could be an important action of some antipsychotic drugs...
  12. ncbi Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder
    E Scarr
    Rebecca L Cooper Research Laboratories, Mental Health Research Institute, Parkville, Victoria, Australia
    Bipolar Disord 5:257-64. 2003
    ..The purpose of this study was to determine whether there are changes in the density of ionotropic glutamate receptors in the hippocampus of subjects with bipolar disorder...
  13. ncbi Decreased serotonin2A receptors in Brodmann's area 9 from schizophrenic subjects. A pathological or pharmacological phenomenon?
    B Dean
    Mental Health Research Institute, Parkville, Victoria, Australia
    Mol Chem Neuropathol 34:133-45. 1998
    ..This study suggests that data obtained from treating rats with antipsychotic drugs cannot be simplistically extrapolated to studies on tissue obtained postmortem from schizophrenic subjects treated with the same drugs...
  14. ncbi [3H]raclopride binding to brain tissue from subjects with schizophrenia: methodological aspects
    B Dean
    Rebecca L Cooper Research Laboratories, Mental Health Research Institute of Victoria, Parkville, Australia
    Neuropharmacology 36:779-86. 1997
    ..We conclude that the binding of [3H]raclopride is dependent on methodology and therefore data from in vitro and in vivo studies using this drug should be interpreted with caution...
  15. ncbi Measurement of dopamine D2-like receptors in postmortem CNS and pituitary: differential regional changes in schizophrenia
    B Dean
    The Rebecca L Cooper Research Laboratory, The Mental Health Research Institute of Victoria, Parkville, Victoria 3052, Australia
    Life Sci 74:3115-31. 2004
    ..Since dopamine D(3) receptors are absent or present at low concentrations in the pituitary, our data would suggest the dopamine D(2) receptor is decreased in that tissue from schizophrenic subjects...
  16. ncbi Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects
    A S Gibbons
    Rebecca L Cooper Research Laboratories, Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    J Affect Disord 116:184-91. 2009
    ..However, there is conflicting evidence regarding the association between individual muscarinic receptors and the two disorders...
  17. ncbi The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia
    J M Crook
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Australia
    Life Sci 64:1761-71. 1999
    ..These data suggest that the muscarinic cholinergic system may be involved in the pathology of schizophrenia...
  18. ncbi Serotonin(2A) receptors are reduced in the planum temporale from subjects with schizophrenia
    D Pralong
    The Rebecca L Cooper Research Laboratories, The Division of Molecular Schizophrenia, The Mental Health Research Institute, Victoria 3052, Parkville, Australia
    Schizophr Res 44:35-45. 2000
    ..These data suggest that a decrease in the density of 5HT(2A) receptors in the planum temporale may be associated with the pathology of schizophrenia...
  19. ncbi Decreased frontal cortical serotonin2A receptors in schizophrenia
    B Dean
    Rebecca L Cooper Research Laboratories, Mental Health Research Institute of Victoria, Parkville, Australia
    Schizophr Res 21:133-9. 1996
    ..These data may indicate that decreased 5HT2A receptors in the frontal cortex are involved in the pathology of schizophrenia...
  20. ncbi Increased levels of SNAP-25 and synaptophysin in the dorsolateral prefrontal cortex in bipolar I disorder
    E Scarr
    Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    Bipolar Disord 8:133-43. 2006
    ....
  21. ncbi Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits
    B Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia
    Curr Drug Targets CNS Neurol Disord 3:217-25. 2004
    ..It is, therefore, timely to review the evolving nature of the mechanisms of action of different antipsychotic drugs...
  22. ncbi Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia
    B Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    Mol Psychiatry 7:1083-91. 2002
    ..01) with schizophrenia but M4R mRNA was only decreased in BA 40 (48 +/- 6.6 vs 89 +/- 9.9, P < 0.005). These data suggest that the M1R, at least in the dorsolateral prefrontal cortex, may have a role in the pathology of schizophrenia...
  23. ncbi Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia
    B Dean
    Molecular Psychiatry Laboratory, The Mental Health Research Institute, The Kevin Myer Building, The University of Melbourne, Victoria 3010, Australia
    Curr Pharm Biotechnol 13:1563-71. 2012
    ....
  24. ncbi Treating schizophrenia: novel targets for the cholinergic system
    T T Money
    The Mental Health Research Institute, Parkville, Victoria, Australia
    CNS Neurol Disord Drug Targets 9:241-56. 2010
    ....
  25. ncbi Decreased phorbol ester binding in the parahippocampal gyrus from subjects with schizophrenia is not associated with changes in protein kinase C
    E Scarr
    Division of Molecular Schizophrenia, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    Mol Psychiatry 7:683-8. 2002
    ..These results suggest that there are changes in molecules capable of binding [(3)H]phorbol 12,13-dibutyrate, other than protein kinase C, in the parahippocampal gyrus from subjects with schizophrenia...
  26. ncbi Muscarinic receptors in schizophrenia
    B Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    Curr Mol Med 3:419-26. 2003
    ..This review presents data from diverse areas of research to argue that it is now imperative that the therapeutic potential of manipulating the activity of muscarinic receptors for the treatment of schizophrenia is fully explored...
  27. ncbi Repeated antidepressant drug treatment, time of death and frequency of handling do not affect [3H]paroxetine binding in rat cortex
    B Dean
    Rebecca L Cooper Research Laboratories, Mental Health Research Institute of Victoria, Parkville, Australia
    Psychiatry Res 73:173-9. 1997
    ..Thus, overall, these data do not suggest changes in [3H]paroxetine binding reported in the human brain tissue would be due to antidepressant drug treatment or time of death...
  28. ncbi Understanding the pathology of schizophrenia: recent advances from the study of the molecular architecture of postmortem CNS tissue
    B Dean
    Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Victoria, Australia
    Postgrad Med J 78:142-8. 2002
    ..Studies using CNS material obtained postmortem clearly show that the pathology of schizophrenia is complex while the polygenetic nature of the illness may be adding to this complexity...
  29. ncbi Potential clozapine target sites on peripheral hematopoietic cells and stromal cells of the bone marrow
    A Pereira
    Division of Molecular Schizophrenia, Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    Pharmacogenomics J 3:227-34. 2003
    ..The functional significance of differential receptor expression while unknown, may argue for neural regulation of hematopoiesis...
  30. ncbi Regional and duration of illness differences in the alteration of NCAM-180 mRNA expression within the cortex of subjects with schizophrenia
    A S Gibbons
    Rebecca L Cooper Research Laboratories, Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    Schizophr Res 112:65-71. 2009
    ..This data suggests NCAM-180 mRNA expression is altered in a regionally-specific manner in schizophrenia and these changes are associated with the early period following diagnosis...
  31. ncbi Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia
    Shirly Amar
    Stanley Research Center, Faculty of Health Science, Ben Gurion University of the Negev, and Mental Health Center, Beer Sheva, Israel
    Int J Neuropsychopharmacol 11:197-205. 2008
    ....
  32. ncbi No change in cortical muscarinic M2, M3 receptors or [35S]GTPgammaS binding in schizophrenia
    Elizabeth Scarr
    The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    Life Sci 78:1231-7. 2006
    ..Given the widespread changes in muscarinic receptors identified in the CNS of subjects of schizophrenia using functional neuroimaging it remains possible that receptors other than the M1 receptor may be altered in different CNS regions...
  33. ncbi Postmortem brain calcineurin protein levels in schizophrenia patients are not different from controls
    Nitsan Kozlovsky
    Stanley Research Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheva, Israel
    Schizophr Res 83:173-7. 2006
    ..Further studies with antibodies against specific CaN catalytic subunit isoforms (presently unavailable) are required to resolve this issue...
  34. ncbi Regionally specific changes in levels of cortical S100beta in bipolar 1 disorder but not schizophrenia
    Brian Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, The University of Melbourne, Parkville, Victoria, Australia
    Aust N Z J Psychiatry 40:217-24. 2006
    ..To determine if levels of the glial-derived proteins S100beta and glial acidic fibrillary protein (GFAP) and the pro- and antiapoptotic proteins p53 and Bcl-2 were altered in the cortex of subjects with schizophrenia or bipolar 1 disorder...
  35. ncbi Serotonin 1a receptor and associated G-protein activation in schizophrenia and bipolar disorder
    Laura Gray
    The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute of Victoria, 155 Oak Street, Parkville, Victoria 3052, Australia
    Psychiatry Res 143:111-20. 2006
    ..These data indicates that there may be subtle changes in serotonin 1a receptors across the cortex in schizophrenia or bipolar I disorder and suggests a gender discordance in receptor levels...
  36. ncbi Genome-wide expression analysis detects eight genes with robust alterations specific to bipolar I disorder: relevance to neuronal network perturbation
    Noriaki Nakatani
    Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Saitama, Japan
    Hum Mol Genet 15:1949-62. 2006
    ..Finally, gene network analysis using the currently obtained expression data highlighted cellular growth and nervous system development pathways as potential targets in the molecular pathophysiology of bipolar disorder...
  37. ncbi Regulator of G-protein signalling 4 expression is not altered in the prefrontal cortex in schizophrenia
    Andrew Stuart Gibbons
    Rebecca L Cooper Research Laboratories, Mental Health Research Institute of Victoria, Parkville, Vic, Australia
    Aust N Z J Psychiatry 42:740-5. 2008
    ..The aim of the present study was to reconcile these discrepancies by examining RGS4 expression in the dorsolateral prefrontal and parietal cortices from subjects with schizophrenia...
  38. ncbi Clozapine bioactivation induces dose-dependent, drug-specific toxicity of human bone marrow stromal cells: a potential in vitro system for the study of agranulocytosis
    Avril Pereira
    Rebecca L Cooper Research Laboratories, Mental Health Research Institute of Victoria, Parkville 3052, Victoria, Australia
    Biochem Pharmacol 72:783-93. 2006
    ....
  39. ncbi Cortical serotonin7, 1D and 1F receptors: effects of schizophrenia, suicide and antipsychotic drug treatment
    Brian Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute, The University of Melbourne, Australia
    Schizophr Res 88:265-74. 2006
    ....
  40. ncbi Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder
    Robert E McCullumsmith
    Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, CIRC 576A 0021, 1530 3rd Avenue South, Birmingham, AL 35294, USA
    Brain Res 1127:108-18. 2007
    ..In the present work, we focus on the expression of these molecules in hippocampus in schizophrenia and bipolar affective disorder I...
  41. ncbi Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia
    Elizabeth Scarr
    Rebecca L Cooper Research Laboratories, Mental Health Research Institute of Victoria, Parkville, Vic, Australia
    Biol Psychiatry 61:1161-70. 2007
    ....
  42. ncbi CNS 14-3-3zeta: changes with sex but not psychiatric diagnoses or psychotropic drug treatment
    Brian Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute, Parkville, Victoria, Australia
    Schizophr Res 93:51-7. 2007
    ..By contrast, our study suggests that levels of 14-3-3zeta in some regions of the human CNS may be modulated by some sex-specific mechanism...
  43. ncbi Gene expression profiling in Brodmann's area 46 from subjects with schizophrenia
    Brian Dean
    Rebecca L Cooper Research Laboratories, Mental Health Research Institute of Victoria, Locked Bag 11, Parkville, VIC 3052, Australia
    Aust N Z J Psychiatry 41:308-20. 2007
    ..To identify altered gene expression in the dorsolateral prefrontal cortex obtained after death from subjects with schizophrenia...
  44. ncbi Plasma apolipoprotein E is decreased in schizophrenia spectrum and bipolar disorder
    Brian Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute, Parkville, Australia
    Psychiatry Res 158:75-8. 2008
    ..Levels of apolipoprotein D were not changed by treatment. Hence changed apolipoprotein E could be involved in abnormalities in lipid homeostasis in some subjects with psychiatric diseases...
  45. ncbi Treatment with haloperidol and diazepam alters GABA(A) receptor density in the rat brain
    Mark C McLeod
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute, Locked Bag 11, Parkville, Victoria, 3052, Australia
    Prog Neuropsychopharmacol Biol Psychiatry 32:560-7. 2008
    ..This outcome may be relevant to the therapeutic benefits of using both drugs in conjunction early in the treatment of a psychotic episode...
  46. ncbi N-Ethylmaleimide sensitive factor in the cortex of subjects with schizophrenia and bipolar I disorder
    Laura Gray
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, 155 Oak St, Parkville, Victoria 3052, Australia
    Neurosci Lett 391:112-5. 2006
    ..These findings highlight the importance of validating findings from high-throughput screening studies and do not support changes in cortical NSF as being of significance in schizophrenia or bipolar 1 disorder...
  47. ncbi Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens
    Suresh Sundram
    The Mental Health Research Institute of Victoria, Locked Bag 11, Parkville, Victoria, 3052, Australia
    Naunyn Schmiedebergs Arch Pharmacol 371:428-33. 2005
    ..If these results can be extrapolated into humans, then this effect of clozapine on the CB1 receptor may be a mechanism that makes it uniquely effective in schizophrenia and comorbid cannabis use...
  48. ncbi Changes in hippocampal GABAA receptor subunit composition in bipolar 1 disorder
    Brian Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    Brain Res Mol Brain Res 138:145-55. 2005
    ....
  49. ncbi High-resolution phosphor imaging: validation for use with human brain tissue sections to determine the affinity and density of radioligand binding
    Geoffrey M Pavey
    The Rebecca L Cooper Research Laboratories, Division of Molecular Schizophrenia, The Mental Health Research Institute of Victoria, Locked Bag 11, Parkville, VIC 3052, Australia
    J Neurosci Methods 116:157-63. 2002
    ..Moreover, the reduced exposure time of phosphor imaging plates (e.g. 7 days vs 5 weeks) allows results to be obtained more rapidly than with conventional film autoradiography...
  50. ncbi The heterogeneity of central benzodiazepine receptor subtypes in the human hippocampal formation, frontal cortex and cerebellum using [3H]flumazenil and zolpidem
    Mark McLeod
    The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute, Locked Bag 11, Parkville, Victoria 3052, Australia
    Brain Res Mol Brain Res 104:203-9. 2002
    ..Moreover, our data suggests that the differential distribution of the zolpidem insensitive component of [3H]flumazenil binding is an indicator of GABA/BZ receptors assembled by different subunits within the human brain...
  51. ncbi Decreased density of [3H]TCP binding following antipsychotic drug withdrawal in rats
    Elizabeth Scarr
    The Molecular Schizophrenia Division, The Mental Health Research Institute of Victoria, Parkville, Australia
    Life Sci 70:2699-705. 2002
    ..1 mg/kg/day) for three months. These data suggest that changes in the NMDA receptor associated ion channels occur following antipsychotic drug withdrawal...
  52. ncbi Changes in the molecular structure of the brain in bipolar disorder: findings using human postmortem brain tissue
    Brian Dean
    Rebecca L Cooper Research Laboratories, Mental Health Research Institute of Victoria, Locked Bag 11, Parkville, Victoria, 3052 Australia
    World J Biol Psychiatry 3:125-32. 2002
    ..Together these studies confirm that the pathology of bipolar disorder is complex but is yielding to intense study of the molecular architecture of postmortem brain tissue from subjects with the illness...
  53. ncbi The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice
    Brian Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    J Neurochem 85:1-13. 2003
    ..In particular, an argument will be developed that the changes in the 5HT2AR in schizophrenia are reflective of a real or perceived change in serotonergic tone and that this forms an important part of the pathology of the illness...
  54. ncbi Cannabis-sensitive dopaminergic markers in postmortem central nervous system: changes in schizophrenia
    Brian Dean
    The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    Biol Psychiatry 53:585-92. 2003
    ..Tyrosine hydroxylase was not different in any diagnostic cohort. CONCLUSIONS: Our data suggests that DAT is decreased in the caudate from THC(-) subjects with schizophrenia, a change that may be reversed by ingesting THC from cannabis...
  55. ncbi Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia
    Brian Dean
    Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    Biol Psychiatry 54:616-22. 2003
    ..It is unclear whether altered expression of a specific isoform of apolipoprotein E (apoE) is associated with the pathology of schizophrenia...
  56. ncbi The neurobiology of bipolar disorder: findings using human postmortem central nervous system tissue
    Brian Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Locked Bag 11, Parkville, Victoria 3052, Australia
    Aust N Z J Psychiatry 38:135-40. 2004
    ..These studies, along with a limited number of functional neuroimaging studies, have been reviewed to provide information on the neurobiology underlying the disorder...
  57. ncbi [3H]RX 821002 in human dorsolateral prefrontal cortex: no changes in postmortem tissue from subjects with schizophrenia
    Brian Dean
    Rebecca L Cooper Research Laboratories, Mental Health Research Institute of Victoria, Victoria, Parkville, Australia
    Psychiatry Res 119:25-31. 2003
    ....
  58. ncbi [(3)H]Flumazenil binding in the human hippocampal formation, frontal cortex and cerebellum detected by high-resolution phosphorimaging
    Mark McLeod
    The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute, Locked Bag 11, Parkville, Victoria, Australia
    Brain Res 926:27-32. 2002
    ....
  59. ncbi Brain distribution of selected antipsychotics in schizophrenia
    Kabrena E Rodda
    Victorian Institute of Forensic Medicine, Department of Forensic Medicine, Monash University, 57-83 Kavanagh Street, Southbank, Vic. 3006, Australia
    Forensic Sci Int 157:121-30. 2006
    ..The regional brain distribution of thioridazine and its metabolites was concentration dependent. These results have implications for determining the role of these drugs in the sudden and unexpected deaths of schizophrenics...
  60. ncbi 5-HT2A and muscarinic receptors in schizophrenia: a postmortem study
    Izuru Matsumoto
    Department of Pathology, University of Sydney, NSW 2006, Australia
    Neurosci Lett 379:164-8. 2005
    ..No significant changes in the density of M1/M4 receptors was observed in these three regions between the two groups. These findings support a possible involvement of the serotonergic system in the pathology of schizophrenia...
  61. ncbi Differential changes in apolipoprotein E in schizophrenia and bipolar I disorder
    Alison Digney
    Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    Biol Psychiatry 57:711-5. 2005
    ..This study extends an initial finding of increased levels of apoE in Brodmann's area (BA) 9 from subjects with schizophrenia to determine if apoE is altered in other brain regions and in brains from subjects with bipolar I disorder (BID)...
  62. ncbi A family-based association study and gene expression analyses of netrin-G1 and -G2 genes in schizophrenia
    Mika Aoki-Suzuki
    Laboratories for Molecular Psychiatry, RIKEN Brain Science Institute, Wako, Japan
    Biol Psychiatry 57:382-93. 2005
    ..We therefore set out to examine the genetic contribution of human NTNG1 and NTNG2 to schizophrenia...
  63. ncbi Hippocampal 5-hydroxytryptamine receptors: abnormalities in postmortem brain from schizophrenic subjects
    Elizabeth Scarr
    The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Australia
    Schizophr Res 71:383-92. 2004
    ..These data support the hypothesis that regionally specific reductions in the density of the 5-HT(2A)R and 5-HT(1F)R are a component of the pathological processes underlying schizophrenia...
  64. ncbi Expression of truncated presenilin 2 splice variant in Alzheimer's disease, bipolar disorder, and schizophrenia brain cortex
    Margaret J Smith
    Department of Pathology, The University of Melbourne, and The Mental Health Research Institute of Victoria, Grattan St, Parkville, Victoria 3010, Australia
    Brain Res Mol Brain Res 127:128-35. 2004
    ..Our findings support previous evidence for increased expression of this variant PS2 isoform in sporadic AD and suggest this isoform may contribute to neurodegeneration...
  65. ncbi Increased levels of serotonin 2A receptors and serotonin transporter in the CNS of neuregulin 1 hypomorphic/mutant mice
    Brian Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute, Parkville, Victoria, Australia
    Schizophr Res 99:341-9. 2008
    ..These data are the first evidence to suggest that NRG1 gene expression may be involved in regulating the development of the serotonergic system in the mammalian CNS...
  66. ncbi GSK-3 parameters in postmortem frontal cortex and hippocampus of schizophrenic patients
    Carmit Nadri
    Stanley Research Center and Zlotowski Center for Neuroscience, Faculty of Health Science, Ben-Gurion University of the Negev, and Mental Health Center, Beersheva, Israel
    Schizophr Res 71:377-82. 2004
    ..Therefore, further investigation in a greater number of brain samples is warranted to better clarify the possible role of this enzyme in the pathophysiology of schizophrenia...
  67. ncbi Imidazopyridines: a novel class of hNav1.7 channel blockers
    Clare London
    Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA
    Bioorg Med Chem Lett 18:1696-701. 2008
    ..Compound 4 had good efficacy (52% and 41% reversal of allodynia at 2 and 4h post-dose, respectively) in the Chung rat spinal nerve ligation (SNL) model of neuropathic pain when dosed orally at 10mg/kg...
  68. ncbi Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimer's disease: no relation to apolipoprotein E expression or genotype
    Elizabeth A Thomas
    Department of Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    Biol Psychiatry 54:136-41. 2003
    ..Progressive cognitive decline is the core clinical feature of AD and is associated with disturbances in the prefrontal cortex...
  69. ncbi M1 receptor agonism, a possible treatment for cognitive deficits in schizophrenia
    Brian Dean
    Neuropsychopharmacology 29:1583-4; author reply 1585-6. 2004
  70. ncbi Isolation and characterization of a UDP-glucuronosyltransferase (UGT1A01) cloned from female rhesus monkey
    Brian Dean
    Department of Drug Metabolism, Merck and Co, Inc, Rahway, NJ 07065, USA
    Arch Biochem Biophys 402:289-95. 2002
    ..Expression of UGT1A01 protein was also detected by a Western blot utilizing a polyclonal antibody developed against the human UGT1A family...
  71. ncbi Consistent with dopamine supersensitivity, RGS9 expression is diminished in the amphetamine-treated animal model of schizophrenia and in postmortem schizophrenia brain
    Philip Seeman
    Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada
    Synapse 61:303-9. 2007
    ..The reduced levels of RGS9-2 expression in both an animal model of schizophrenia and a postmortem schizophrenia brain provide further evidence implicating RGS9-2 as a candidate gene in schizophrenia...
  72. ncbi Role of muscarinic receptors in the pathology of schizophrenia
    Brian Dean
    Am J Med Genet B Neuropsychiatr Genet 126:8-9. 2004